
COYA Stock Forecast & Price Target
COYA Analyst Ratings
Bulls say
Coya Therapeutics is a promising player in the biotech industry, with a focus on developing innovative therapies for chronic diseases with high unmet medical needs. Despite the risks associated with regulatory and clinical success, the company's current pipeline, including the COYA-302 combination strategy and the FTD and ALS treatment programs, has the potential for substantial growth and market exclusivity. However, the company will need to secure additional funding in the future, which may be challenging in the competitive biotech market.
Bears say
Coya Therapeutics is a clinical-stage biotechnology company that may face potential financing risks and is heavily reliant on the success of its lead product candidate, COYA 302. Additionally, the market for SMid-Cap stocks has been volatile without company-specific fundamental reasons, which may result in substantial losses for investors. Furthermore, the company faces significant competition from other major pharmaceutical companies and specialized biotechnology firms. These factors, along with the need for future fundraising and potential regulatory hurdles, contribute to the negative outlook on Coya Therapeutics' stock.
This aggregate rating is based on analysts' research of Coya Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
COYA Analyst Forecast & Price Prediction
Start investing in COYA
Order type
Buy in
Order amount
Est. shares
0 shares